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Background: Because the predictive significance of previously reported racial differences
in leptin and adiponectin levels remains unclear, we assessed the prospective association
of these adipokines with the risk of cardiovascular disease (CVD) events in African Ameri-
cans, a population with a high prevalence of cardiometabolic risk factors.
Methods: Serum specimens from 4,571 Jackson Heart Study participants without preva-
lent CVD at baseline examination (2000–2004) were analyzed for adiponectin and leptin
levels. Cox proportional hazard regression models were used to estimate the associations
of the two adipokines with incident coronary heart disease (CHD) and incident ischemic
stroke.
Results: During 6.2 years average of follow-up, 98 incident CHD and 87 incident ischemic
stroke events were documented. Among study participants (64% women; mean age
54±13 years), the mean (standard deviation, SD) was 6.04 (4.32)µg/mL in women and 4.03
(3.14) µg/mL in men for adiponectin and 37.35 (23.90) ng/mL in women and 11.03 (10.05)
ng/mL in men for leptin. After multivariable adjustment that included age, body mass index,
high-density lipoprotein cholesterol, triglycerides, C-reactive protein, insulin resistance by
homeostasis model assessment for insulin resistance, systolic blood pressure, hyperten-
sion medication, smoking, and physical activity, adiponectin was directly associated in
women with incident stroke, HR=1.41 (1.04–1.91) per one SD increase (p=0.03), but not
in men (p=0.42). It was not associated with incident CHD in women or men. Leptin was
not associated with incident CHD or incident stroke.
Conclusion: In the largest community-based African American cohort, adiponectin was
associated among women with a higher risk of incident stroke. Whether adiponectin har-
bors harmful properties, or it is produced in response to vascular inflammation to counter
the atherosclerotic process, or the putative “adiponectin resistance” phenomenon acts,
should be further assessed.
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INTRODUCTION
Significant research has been conducted in order to understand
the obesity mechanisms related to cardiovascular disease (CVD)
pathogenesis (1). It is now evident that adipose tissue is more
than an energy storage compartment; it is a secretory organ for
bioactive molecules known as adipokines (2). Adipokines such
as leptin and adiponectin contribute to the pathophysiology of
obesity-related disorders through their properties to modulate
inflammatory and metabolic processes. In population studies lep-
tin is directly associated with coronary heart disease (CHD) and
ischemic stroke (3–7), but leptin’s proatherogenic properties in
animal models are not clear (8, 9). Opposite to leptin, adiponectin
is atheroprotective in animal models but epidemiological investi-
gations evaluating its role in CVD have been contradictory (10,11).
Thus, given the conflicting studies in animal and human research
and the reported racial differences in adipokine levels (12–14), we
assessed the prospective association of the two adipokines with the
risk of CVD events in African American participants in the Jackson
Heart Study (JHS). Our study hypotheses were that there is a direct
association between serum leptin levels and incident CVD (CHD
and stroke) and an inverse association between serum adiponectin
levels and incident CVD.
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Because previous studies indicated gender-differences in the
association of leptin and adiponectin with CVD (5, 15, 16), we
also assessed if gender modifies the association of these adipokines
with CVD events. Our a priori hypothesis was that there are differ-
ences by gender for these associations. We also assessed the effect
modification by age groups, as previous studies reported a direct
association between adiponectin and incident CHD among older
individuals (17).
MATERIALS AND METHODS
STUDY POPULATION
The JHS is a single-site, prospective cohort study of the risk factors
and causes of heart disease in adult African Americans. A probabil-
ity sample of 5,301 African Americans, aged 21–94 years, residing
in a three county area surrounding the city of Jackson, MS, USA
were recruited and examined at baseline (2000–2004) by certified
technicians according to standardized protocols. Clinic visits and
interviews occur approximately every 4 years. Annual follow-up
interviews and cohort surveillance are ongoing. An overview of
the JHS (18) and details of the study design (19), recruitment
protocol (20), and data collection methods (19) are published
elsewhere. The present study included 4,571 participants who had
plasma leptin (n= 4,552) or plasma adiponectin (n= 4,554) mea-
sured using frozen specimens stored at JHS Exam 1 (2000–2004).
Written consent was obtained from each participant at the incep-
tion of the study, and the study was approved by the participating
JHS institutions: Jackson State University, Tougaloo College, and
the University of Mississippi Medical Center. The study proto-
col for the ascertainment of the leptin and adiponectin samples
was approved by the Morehouse School of Medicine Institutional
Review Board.
ASCERTAINMENT AND ADJUDICATION OF CARDIOVASCULAR
DISEASES INCIDENT EVENTS
Trained interviewers conduct telephone annual follow-up inter-
views to ascertain any significant health events since the last
JHS contact, including diagnostic tests, hospitalizations, or death.
Information on cohort hospitalizations and deaths is transmitted
to the medical record abstraction unit who review death certifi-
cates and hospital records to identify CVD events in the cohort.
Interviews with the next of kin and completed questionnaires by
physicians and medical examiners or coroners are used to obtain
information on deaths in the cohort. A computer-generated diag-
nosis with follow-up review and adjudication by trained medical
personnel completes final, disease-specific event classification of
hospitalized and fatal CHD and stroke (21).
LEPTIN AND ADIPONECTIN MEASUREMENTS
Venous blood samples were withdrawn from each subject at base-
line examination after more than 8 h of fasting as described
elsewhere (19). Vials of serum were stored at the JHS central
repository in Minneapolis, MN, USA at−80 °C until assayed. Lep-
tin was analyzed with Human Leptin RIA kit (LINCO Research,
St Charles, MI, USA) and the acceptable coefficients of variation
was 10% (22). Adiponectin concentration was measured as total
adiponectin by an ELISA system (R&D Systems; Minneapolis, MN,
USA) (23). The inter-assay coefficient of variation was 8.8%. No
biological degradation has been described using stored specimens,
indicating a high validity for our measurements. We measured
CRP using immunoturbidimetric CRP-Latex assay from Kamiya
Biomedical Company following manufacturer’s high-sensitivity
protocol. The inter-assay coefficients of variation on control sam-
ples repeated in each assay were 4.5 and 4.4% at CRP concentra-
tions of 0.45 and 1.56 mg/L respectively. The reliability coefficient
for masked quality-control replicates was 0.95 for the CRP assay.
CVD RISK FACTORS USED AS COVARIATES
Cardiovascular disease risk factor information was ascertained
during the JHS Exam 1 (2000–2004) through standard procedures
and questionnaires. In all participants, the clinic visit included
physical examinations, anthropometry, survey of medical history,
and current medication use and collection of blood and urine
specimens for biological assessment. In-clinic standing height and
weight were measured in lightweight examination clothing with-
out shoes or constricting garments. We calculated BMI as weight
in kilograms divided by height in meters squared (kg/m2). The
average of two sitting blood pressure, measured at 1-min inter-
vals after a 5-min silent rest, was used for analysis. Participants
were considered current smokers if they smoked at the time of the
baseline examination. Current alcohol use was defined as “yes” if
they drank in the past 12 months. Lipid variables, fasting plasma
glucose, and fasting insulin were measured using standard lab-
oratory techniques. Insulin resistance was calculated using the
homeostasis model assessment for insulin resistance (HOMA-
IR), and used as a continuous variable. Physical activity was
assessed with a physical activity survey instrument administered
by interview. The questionnaire assessed four different domains
of physical activity (active living, work, home and garden, and
sport and exercise indexes). A total score was composed as the
sum of these domains (maximum of 24), with a higher score
indicating a higher level of total physical activity (24). Antihy-
pertensive and lipid-lowering medications were assessed during
the baseline exam.
STATISTICAL ANALYSIS
For each individual CVD risk factor, the Student unpaired t -test or
the chi-square test was performed in order to assess the significance
of the difference between participants with and without events.
The relationships between logarithmically transformed leptin, log-
arithmically transformed adiponectin, and CVD risk factors were
assessed by calculating partial correlation coefficients adjusted for
age. A proportional hazard regression model was used to assess the
association of either incident CHD or incident stroke as depen-
dent variables with log-leptin or log-adiponectin [both expressed
per one standard deviation (SD) increase in the log-transformed
values], using the CVD risk factors as independent variables for
the adjustment. The effect measure modification potential of gen-
der and age groups (defined using the median age of 55 years) was
assessed using interaction terms in the fully adjusted models. In
additional analyses we queried the associations between the two
adipokines and hemorrhagic stroke. We conducted also sensitivity
analyses in which we excluded participants with prevalent atrial
fibrillation in order to assess if the associations are confounded by
preexisting heart failure determinants (more prevalent in African
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Americans). All computations were performed by SAS software
version 9.2 (SAS® Institute Inc., Cary, NC, USA).
RESULTS
Our study sample, composed of 2,924 women (64%) and 1,647
men, had a mean (SD) age of 54 (13) years. During a mean
of 6.2 years of follow-up, 98 incident CHD and 87 incident
ischemic stroke events were documented. The unadjusted mean
(SD) adiponectin levels were 6.04 (4.32) µg/mL in women and
4.03 (3.14)µg/mL in men. For leptin, the levels were 37.35 (23.90)
ng/mL in women and 11.03 (10.05) ng/mL in men. The character-
istics of the participants according to presence or absence of the
two incident conditions and by gender are presented in Table 1.
Among women, there was a statistically significant difference
between participants with incident CHD and those without for
the majority of covariates with the exception of HDL-cholesterol
and C-reactive protein. Notably, adiponectin was higher among
those with incident CHD events compared with those without
(Table 1). In both men and women, participants with incident
stroke had higher values of systolic blood pressure/blood pressure
medication but lower physical activity levels. Women with incident
stroke had also higher levels of fasting plasma glucose (Table 1).
CORRELATIONS BETWEEN LEPTIN AND ADIPONECTIN AND OTHER
VARIABLES
Age-adjusted correlates of log-transformed leptin and adiponectin
with the CVD risk factors considered in our study are presented
in Table 2. Among both men and women, adiponectin and lep-
tin were significantly correlated with all the risk factors with the
exception of systolic blood pressure. Among men, adiponectin
was not significantly correlated with C-reactive protein. Lep-
tin was highly positively correlated with BMI and HOMA-IR
in both women and men (r = 0.66 in women and r = 0.73 in
men, for BMI and r = 0.38 in women and r = 0.50 in men, for
HOMA-IR). Adiponectin was highly positively correlated with
HDL-cholesterol (r = 0.37 in women and r = 0.39 in men) and
negatively correlated with HOMA-IR (r =−0.41 in women and
r =−0.30 in men; Table 2).
MULTIVARIABLE-ADJUSTED HAZARD REGRESSION MODELS OF LEPTIN
AND ADIPONECTIN
No effect modification for gender was observed for the associ-
ation of serum adiponectin and leptin with incident CHD (p
for interaction= 0.38) or stroke (p for interaction= 0.77). How-
ever, we kept the analyses stratified by gender given the observed
gender-differences in these associations. No effect modification
for age group was observed for the association of adiponectin
with incident CHD (p for interaction= 0.56). The results of
the multivariable proportional hazard regression analyses for the
gender-specific associations of log-transformed adiponectin and
leptin with incident CHD and stroke are presented in Table 3.
Among women, the hazard ratio (95% confidence interval) of
incident stroke per one SD increase in log-adiponectin was 1.41
(1.04–1.91); p-value of 0.03. Notably, no association was present
Table 1 | Sex-specific descriptive characteristics of the JHS participants with and without incident CHD/stroke eventsa.
No conditions Incident CHD Incident stroke
Women Men Women Men Women Men
Participants (N ) 2,889 1,602 60 38 56 31
BMI (kg/m2) 32.9 (7.7) 29.8 (6.2) 30.3 (5.7)b 29.5 (5.5) 32.6 (6.5) 29.8 (5.2)
Adiponectin (µg/mL) 6.0 (4.3) 4.0 (3.1) 7.8 (6.1)b 5.3 (4.3)b 7.0 (5.4) 5.0 (3.8)
Leptin (ng/mL) 37.3 (23.8) 10.9 (10.1) 37.5 (31.4)b 14.4 (10.5)b 41.9 (28.4) 12.6 (9.9)
HDL-C (mmol/L) 1.41 (0.37) 1.18 (0.32) 1.41 (0.39) 1.13 (0.28) 1.45 (0.42) 1.14 (0.37)
TG (mmol/L) 1.13 (0.77) 1.33 (1.36) 1.35 (0.77)b 1.49 (1.30) 1.35 (0.84)b 1.70 (1.53)
FPG (mg/mL) 98.4 (31.6) 98.7 (29.2) 114.2 (43.1)c 117.0 (53.2)b 115.5 (46.1)c 110.2 (50.7)
CRP (mg/L) 5.9 (8.3) 3.4 (9.9) 6.3 (11.4) 3.1 (3.3) 6.9 (11.4) 14.7 (6.0)d
HOMA-IR 3.8 (2.4) 3.4 (2.4) 3.4 (1.7) 3.4 (1.6) 3.8 (2.0) 3.7 (2.9)
SBP (mm Hg) 125.4 (17.9) 127.0 (17.1) 138.0 (22.9)d 134.7 (19.4)b 145.6 (28.6)d 140.3 (24.0)d
CVD events (%) 0 0 2.06 2.32 1.92 2.36
Antihypertensive medication (%) 53.1 39.3 82.8d 88.9d 76.4c 74.1d
Lipid-lowering medication (%) 11.1 9.1 20.0b 32.4d 7.6 11.5
Current smoking (%) 14.3 22.3 25.0b 39.5b 16.1 25.8b
Alcohol use (%) 40.5 61.1 28.3 44.7b 22.2b 54.8
Physical activity 8.4 (2.5) 8.9 (2.6) 6.7 (2.1)d 7.1 (2.3)d 7.0 (2.6)d 7.6 (2.7)b
aData are presented as mean±SD or as percentage when appropriate.
bp<0.05 for sex-specific comparison between groups.
cp<0.001 for sex-specific comparison between groups.
dp<0.0001 for sex-specific comparison between groups.
BMI indicates body mass index; HDL-C, high-density lipoprotein cholesterol;TG, triglycerides; SBP, systolic blood pressure; FPG, fasting plasma glucose; CRP, C-reactive
protein; HOMA-IR, insulin resistance by homeostasis assessment model HOMA-IR; CHD, coronary heart disease; CVD, cardiovascular diseases.
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Table 2 | Age-adjusted partial correlations of log-adiponectin and log-leptin to individual cardiovascular risk factors/study covariates.
Variable Adiponectin Leptin
Women (N =2,911) Men (N =1,643) Women (N =2,913) Men (N =1,639)
r p-Value r p-Value r p-Value r p-Value
Adiponectin – – – – −0.22 <0.0001 −0.22 <0.0001
Leptin −0.22 <0.0001 −0.22 <0.0001 – – – –
BMI −0.23 <0.0001 −0.22 <0.0001 0.66 <0.0001 0.73 <0.0001
SBP 0.02 0.36 0.02 0.49 0.02 0.23 0.10 0.0002
HDL-C 0.36 <0.0001 0.39 <0.0001 −0.12 <0.0001 −0.29 <0.0001
TG −0.27 <0.0001 −0.30 <0.0001 0.11 <0.0001 0.26 <0.0001
FPG −0.25 <0.0001 −0.16 <0.0001 0.22 <0.0001 0.26 <0.0001
CRP −0.17 <0.0001 −0.03 0.26 0.25 <0.0001 0.06 0.02
HOMA-IR −0.40 <0.0001 −0.31 <0.0001 0.38 <0.0001 0.50 <0.0001
HR indicates hazard ratio.
Table 3 | Associationsa of adiponectin and leptin with incident coronary heart disease and stroke in the Jackson Heart Study (N =4,571).
Incident coronary
heart disease (N =98)
Incident stroke (N =87)
HR 95% C.I. p-Value HR 95% C.I. p-Value
Adiponectin
Womenb (n=2,911) 1.32 0.99–1.77 0.06 1.41 1.04–1.91 0.03
Men (n=1,627) 0.90 0.56–1.47 0.68 1.18 0.79–1.74 0.42
Leptinc
Women (n=2,913) 1.35 0.78–2.35 0.29 0.99 0.64–1.55 0.98
Men (n=1,639) 1.18 0.62–2.24 0.62 0.57 0.19–1.68 0.31
aModels were adjusted for age, body mass index, systolic blood pressure, blood pressure medication, HDL-cholesterol, triglycerides, C-reactive protein, insulin resis-
tance by HOMA-IR, smoking, and physical activity.
bp-Value for interaction of adiponectin by gender was 0.38 for incident CHD and 0.77 for incident stroke.
cp-Value for interaction of leptin by gender was 0.06 for incident CHD and 0.76 for incident stroke.
among men between adiponectin and incident CHD or incident
stroke. No association was detected between leptin and incident
CHD or stroke for neither women or men (Table 3). Due to very
few hemorrhagic stroke events (N = 3), the association between
adiponectin and hemorrhagic stroke [2.05 (0.74–5.66)] was unre-
liable due to a very large confidence interval. In the sensitivity
analysis with exclusion of participants with prevalent atrial fibril-
lation, the association between adiponectin and ischemic stroke
was statistically significant, 1.30 (1.01–1.67).
DISCUSSION
PRINCIPAL FINDINGS
Our study carried out in the largest community-based sample of
African Americans showed that among women, but not among
men, adiponectin was associated with incident ischemic stroke.
No association was present between leptin and incident CHD
or incident stroke. Nevertheless, adiponectin levels were signifi-
cantly higher among the participants with incident CHD events
compared with those without.
IN THE CONTEXT OF PREVIOUS LITERATURE
Very few previous investigations have assessed among African
Americans the associations of adiponectin or leptin with incident
CVD events (12, 17). In an investigation within the Cardiovas-
cular Health Study (CHS) with 3,300 participants (that included
approximately 700 African Americans), there was no association
between adiponectin and incident CHD after adjusting for CVD
risk factors (17). Thus, our findings of no association between
adiponectin and incident CHD align with some of the previous
findings.
Our results indicating a higher level of adiponectin among
participants with incident CHD are intriguing but not at odds
with some of the previous studies. Adiponectin is an adipose
tissue-derived collagen-like protein that beneficially affects many
pathways that may be relevant for the development of athero-
sclerosis, including glucose and lipid metabolism, inflammation,
endothelial function, as well as thrombogenesis, and it is therefore
supposed to protect from CHD and ischemic stroke (11). Exper-
imental in vitro and animal studies have shown that adiponectin
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beneficially affects many pathways that may be related to the devel-
opment of CVD. Administration of adiponectin in animal models
improves insulin sensitivity and may have anti-atherogenic and
anti-inflammatory properties (25, 26). Moreover, in some case-
control studies, individuals with CHD or cerebrovascular disease
have lower adiponectin levels than healthy controls (25, 26). This
association generally follows a “dose-response” relationship, with
lower adiponectin levels in more severe forms of CHD (27).
However, results from prospective studies in humans provide
inconsistent results, with only some showing significant inverse
associations between adiponectin and risk of CHD (28–32). In the
Health Professionals Follow-up Study, men who were free of diag-
nosed CVD and who were in the highest compared to the lowest
quintile of adiponectin levels had a significantly 44% decreased
risk of subsequent CHD over 6-year follow-up, independent of
other cardiovascular risk factors (33). These observations were
confirmed among diabetic men in this same cohort (28), and by
an 8-year follow-up study of men reported by Frystyk et al. (29).
Consistent with these findings, low plasma adiponectin levels have
been shown to predict the progression of coronary calcification
(34). The Strong Heart Study, including individuals of American
Indian heritage with a very high prevalence of type 2 diabetes,
and the male British Regional Heart Study observed inverse rela-
tionships between adiponectin and risk of CHD, associations that
became nevertheless non-significant after adjustment for risk fac-
tors (30, 35). Additionally, Kuller et al. reported no significant
association with risk of fatal CHD among men with the metabolic
syndrome during 18 years of follow-up (36). Similarly, the MON-
ICA/KORA study in Germany did not find a significant inverse
association between adiponectin and risk of CHD (16). Moreover,
a recent investigation in prospectively enrolled diabetic patients
suffering with ischemic heart disease and following them up for a
just over a year (37), the group with higher levels of adiponectin
unexpectedly had a higher rate of a composite end point compris-
ing cardiac and cerebral events. Similarly, among participants with
higher levels of adiponectin, there was a direct association between
adiponectin and incident CHD in a nested case-control within
the CHS cohort (38). In the Health ABC biracial cohort, higher
circulating concentrations of adiponectin were associated with
higher risk of CHD in older African Americans, even accounting
for CHD risk factors (12). A doubling of adiponectin was associ-
ated with a 37% higher risk of incident CHD (hazards ratio, 1.37;
95% confidence interval, 1.01–1.87) after multivariable adjust-
ment (12). Therefore, it can be concluded that although several
studies reported an inverse association between adiponectin levels
and CHD there are investigations that indicated the opposite.
In terms of cerebrovascular events and the two adipokines, our
finding of a direct association between higher adiponectin lev-
els and incident stroke is intriguing. Several investigations have
shown that low adiponectin levels were associated with disturbed
glucose metabolism but not with the risk of ischemic stroke (4, 39–
41). The data on adiponectin are nevertheless conflicting, with
even large prospective studies yielding opposing results. These
discrepancies are probably due to the different characteristics
of the populations studied (42). Our African American popu-
lation has a very high prevalence for the majority of CVD risk
factors, especially BMI. This seems to be the cause of a relatively
larger variance for the two adipokines studied when compared
with white populations (33, 43), and might be an explanation
for our findings. In a different direction, leptin appears more as
a reasonable predictor of stroke, especially hemorrhagic stroke,
based on the majority of the available evidence (3, 44, 45). In
our previous investigation to examine the association of increased
plasma leptin concentration with prevalent stroke and CHD, lep-
tin was significantly associated with stroke only in women, and
no significant association was observed in men (22). As showed
in our current investigation using longitudinal data, the associa-
tion did not persist. It remains to be seen, using future events, if
this null association is not due to relatively few incident events
available. Nonetheless, our current investigation in African Amer-
icans in JHS adds valuable information because this association
of adiponectin with stroke is less assessed and it is the subject of
significant controversy.
In regards to the gender-differences that we found within our
study population, the information that we have for adiponectin
is derived mainly from cohorts that were exclusively composed of
one gender only. For example, prospective studies of the associa-
tion of circulating adiponectin levels with risk of CHD have been
conducted predominantly among male populations. As an excep-
tion, the British Women’s Heart and Health Study found a non-
significant inverse relationship between adiponectin and CHD
(35). In that study, high molecular weight (HMW) adiponectin
and the HMW to total adiponectin ratio were also not signifi-
cantly related to risk of CHD (46). However, the sample size in
that study was limited, including only 167 cases and 333 controls.
In the 20-year prospective analysis of the Rancho Bernardo Study,
high plasma adiponectin levels were related to a significantly lower
risk of non-fatal CHD among men only, whereas adiponectin was
not significantly associated with risk of fatal CHD in either sex
(15). Non-fatal events among women were not available in that
report. In the KORA study, adiponectin levels were not related
to risk of CHD among women (16). In a meta-analysis by Sat-
tar et al. (47), leptin was not associated with CHD events among
women enrolled in the British Women’s Heart Health Study, but
significantly associated with CHD among men enrolled in the
Northern Sweden investigation. In aggregate this meta-analysis
found a statistically non-significant association between leptin
and CHD risk that attenuated to the null following adjustment
for BMI (47). Leptin was not associated with ischemic stroke
among postmenopausal women recruited in the Women’s Health
Initiative (48). Leptin was associated with stroke among men
but not among women participants from the Northern Sweden
study (4).
POTENTIAL MECHANISMS
It is intriguing to speculate that an explanation for our find-
ings of a direct association between adiponectin and incident
stroke is the phenomenon of “adiponectin resistance,” which has
been advanced to explain paradoxical increases in adiponectin-
associated adverse outcomes (26, 49). An alternative explanation
is that adiponectin is produced in response to vascular inflamma-
tion to counter the atherosclerotic process (50, 51). According to
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this hypothesis, adiponectin would serve as a marker of disease
severity in patients with clinical CVD or older adults with subclin-
ical CVD, but not to the same degree in younger populations free
of prevalent CVD. There is also the possibility that, in addition to
its protective actions, adiponectin has direct harmful effects, which
could be more operative in older individuals. Indeed, adiponectin
has increased energy expenditure through direct actions in the
central nervous system in mice (52), an effect that, if present
in humans, could be particularly deleterious in older adults by
potentially accelerating sarcopenia. Notable, in our study age was
not an effect modifier of the association of adiponectin with inci-
dent CHD. In a different direction, the HMW adiponectin isoform
appears to be the most potent activator of insulin-sensitizing (25)
and anti-atherogenic (53) pathways. This raises the possibility that
the heterogeneous epidemiological findings reported thus far for
total adiponectin could relate to different proportions of HMW
adiponectin. We are not able at present to confirm this, as HMW
adiponectin is not yet available within our cohort. On the other
hand, the relatively higher prevalence of heart failure known to be
present in African American women does not seem to explain the
present association as similar results were obtained after excluding
participants with prevalent atrial fibrillation. Further multiracial
investigations should query if the association that we found is
racially or gender driven.
IMPLICATIONS
Despite documented preclinical cardiometabolic benefits and
favorable cross-sectional clinical associations, elevated concentra-
tions of circulating adiponectin are associated with a significantly
increased risk of incident ischemic stroke among women. These
findings suggest that, adiponectin has putative harmful properties.
Whether in our population of African Americans with a relatively
high prevalence of cardiometabolic risk factors adiponectin har-
bors harmful properties, or it is produced in response to vascular
inflammation to counter the atherosclerotic process, or the puta-
tive “adiponectin resistance” phenomenon acts, should be further
investigated.
STRENGTHS AND LIMITATIONS
The main strength of our investigation is that this study addresses
important research questions using prospective CVD events data
from the largest community-based sample of African Americans,
the JHS, a cohort with a strict protocol of follow-up and high
quality-control data. On the other hand, generalizability to other
ethnic group cannot be applied. Another limitation is the relative
low number of participants with incident CVD events, as incident
events are accumulating.
CONCLUSION
In the largest community-based sample of African Americans,
there is a direct association between adiponectin and incident
stroke among women but not among men, an association that
deserves further investigation.
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